[HTML][HTML] The role of macrophages in cancer development and therapy

E Cendrowicz, Z Sas, E Bremer, TP Rygiel - Cancers, 2021 - mdpi.com
Simple Summary Tumor-Associated Macrophages (TAMs) play an important role in the
development of tumors, modulation of neoangiogenesis, immune suppression, and …

[HTML][HTML] Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials

F Tang, Y Tie, YQ Wei, CQ Tu, XW Wei - Biochimica et Biophysica Acta …, 2021 - Elsevier
Sarcomas represent a distinct group of rare malignant tumors with high heterogeneity.
Limited options with clinical efficacy for the metastatic or local advanced sarcoma existed …

[HTML][HTML] Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment—Progresses in Their Use in Combined Cancer …

A Povo-Retana, R Landauro-Vera, C Alvarez-Lucena… - Molecules, 2024 - mdpi.com
Trabectedin (TRB) and Lurbinectedin (LUR) are alkaloid compounds originally isolated from
Ecteinascidia turbinata with proven antitumoral activity. Both molecules are structural …

Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma

J Martin-Broto, A Olarte-García… - … in medical oncology, 2024 - journals.sagepub.com
Background and objectives: Dimensional response is an unmet need in second lines of
advanced soft tissue sarcomas (STS). Indeed, the three approved drugs, pazopanib …

Risk factors for the development of local recurrence in extremity soft-tissue sarcoma

F Tirotta, R Sayyed, RL Jones… - Expert Review of …, 2022 - Taylor & Francis
Introduction Local recurrence (LR) is one of the main pitfalls in surgery for extremities soft
tissue sarcoma (eSTS). Achieving clear histopathological margins is the most important …

Optimal prognostic factors for metastatic and inoperable sarcomas treated with pazopanib, eribulin, and trabectedin

T Iwai, M Hoshi, N Oebisu, N Takada, Y Ban, H Yao… - in vivo, 2023 - iv.iiarjournals.org
Background/Aim: The prognosis of metastatic and inoperable sarcomas is extremely poor,
and intensive chemotherapy-based treatment is typically administered to prolong survival …

[HTML][HTML] HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study

DS Moura, JL Mondaza-Hernandez… - Cellular and Molecular …, 2024 - Springer
HMGA1 is a structural epigenetic chromatin factor that has been associated with tumor
progression and drug resistance. Here, we reported the prognostic/predictive value of …

Local Therapies for Metastatic Sarcoma: Why, When, and How?

N Hindi, N Laack, K Hong… - American Society of …, 2023 - ascopubs.org
Management of patients with advanced sarcoma has been evolving in recent decades, from
a one-fit-all perspective to a more refined, personalized, and multidisciplinary approach. In …

Experience with second-line trabectedin in daily clinical practice: case studies

J Martín-Broto, N Hindi, G Grignani, A Merlini… - Future …, 2022 - Taylor & Francis
As a recommended second-line option for advanced soft tissue sarcoma, trabectedin can
provide the necessary balance between long-term tumor control and preserved quality of …

What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?

N Hindi, J Martin-Broto - Current Opinion in Oncology, 2021 - journals.lww.com
What is the standard indication of adjuvant or neoadjuvant c... : Current Opinion in Oncology
What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue …